Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 2-3, January 2004

Radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician

  • Peter S. Conti

      Affiliations

    • Departments of Radiology, Clinical Pharmacy, and Biomedical Engineering, University of Southern California, Los Angeles, CA, USA
    • *Address reprint requests to Peter S. Conti, MD, PhD, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    • 1Dr Conti serves as a consultant and member of the speakers’ bureau for Biogen Idec Inc.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0001-2998(03)00080-1

doi:10.1053/j.semnuclmed.2003.11.003

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 2-3, January 2004

Article Tools